Emanuele Crocetti1, Sandra Mallone2, Trude Eid Robsahm3, Anna Gavin4, Domenic Agius5, Eva Ardanaz6, Maria-Dolores Chirlaque Lopez7, Kaire Innos8, Pamela Minicozzi9, Lorenzo Borgognoni10, Daniela Pierannunzio2, Nora Eisemann11. 1. UO Epidemiologia Clinica, Descrittiva e Registri - ISPO, Firenze, Italy. Electronic address: emanuelecrocetti@yahoo.com. 2. Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità, Roma, Italy. 3. Cancer Registry of Norway, Institute of Population Based Cancer Research, Oslo, Norway. 4. Northern Ireland Cancer Registry, Centre for Public Health, Queens University, Belfast, Northern Ireland, UK. 5. Malta National Cancer Registry, Department of Health Information and Research, Pieta, Malta. 6. Navarra Cancer Registry, Navarra Public Health Institute, Pamplona, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. 7. Servicio de Epidemiología, Department of Epidemiology, Consejería de Sanidad, Murcia Health Authority, Murcia, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. 8. Department of Epidemiology and Biostatistics National, Institute for Health Development, Tallinn, Estonia. 9. Analytical Epidemiology and Health Impact Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 10. SC Chirurgia Plastica e Ricostruttiva, Ospedale S.M. Annunziata - Azienda Sanitaria di Firenze Centro di Riferimento Regionale per il Melanoma, Istituto Toscano Tumori, Firenze, Italy. 11. Institute of Cancer Epidemiology, University of Luebeck, Luebeck, Germany.
Abstract
BACKGROUND: In Europe skin melanoma (SM) survival has increased over time. The aims were to evaluate recent trends and differences between countries and regions of Europe. METHODS: Relative survival (RS) estimates and geographical comparisons were based on 241,485 patients aged 15years and over with a diagnosis of invasive SM in Europe (2000-2007). Survival time trends during 1999-2007 were estimated using the period approach, for 213,101 patients. Age, gender, sub-sites and morphology subgroups were considered. RESULTS: In European patients, estimated 5-year RS was 83% (95% confidence interval, CI 83-84%). The highest values were found for patients resident in Northern (88%; 87-88%) and Central (88%; 87-88%) Europe, followed by Ireland and United Kingdom (UK) (86%; 85-86%) and Southern Europe (83%; 82-83%). The lowest survival was in Eastern Europe (74%; 74-75%). Within regions the intercountry absolute difference in percentage points of RS varied from 4% (North) to 34% (East). RS decreased markedly with patients' age and was higher in women than men. Differences according to SM morphology and skin sub-sites also emerged. Survival has slightly increased from 1999 to 2007, with a small improvement in Northern and the most pronounced improvement in Eastern Europe. DISCUSSION: SM survival is high and still increasing in European patients. The gap between Northern and Southern and especially Eastern European countries, although still present, diminished over time. Differences in stage distribution at diagnosis may explain most of the geographical differences. However, part of the improvement in survival may be attributed to overdiagnosis from early diagnosis practices.
BACKGROUND: In Europe skin melanoma (SM) survival has increased over time. The aims were to evaluate recent trends and differences between countries and regions of Europe. METHODS: Relative survival (RS) estimates and geographical comparisons were based on 241,485 patients aged 15years and over with a diagnosis of invasive SM in Europe (2000-2007). Survival time trends during 1999-2007 were estimated using the period approach, for 213,101 patients. Age, gender, sub-sites and morphology subgroups were considered. RESULTS: In European patients, estimated 5-year RS was 83% (95% confidence interval, CI 83-84%). The highest values were found for patients resident in Northern (88%; 87-88%) and Central (88%; 87-88%) Europe, followed by Ireland and United Kingdom (UK) (86%; 85-86%) and Southern Europe (83%; 82-83%). The lowest survival was in Eastern Europe (74%; 74-75%). Within regions the intercountry absolute difference in percentage points of RS varied from 4% (North) to 34% (East). RS decreased markedly with patients' age and was higher in women than men. Differences according to SM morphology and skin sub-sites also emerged. Survival has slightly increased from 1999 to 2007, with a small improvement in Northern and the most pronounced improvement in Eastern Europe. DISCUSSION: SM survival is high and still increasing in European patients. The gap between Northern and Southern and especially Eastern European countries, although still present, diminished over time. Differences in stage distribution at diagnosis may explain most of the geographical differences. However, part of the improvement in survival may be attributed to overdiagnosis from early diagnosis practices.
Authors: M D Chirlaque; D Salmerón; J Galceran; A Ameijide; A Mateos; A Torrella; R Jiménez; N Larrañaga; R Marcos-Gragera; E Ardanaz; M Sant; P Minicozzi; C Navarro; M J Sánchez Journal: Clin Transl Oncol Date: 2017-07-17 Impact factor: 3.405
Authors: Liesbeth Sondermeijer; Lieke G E Lamboo; Anne C de Waal; Tessel E Galesloot; Lambertus A L M Kiemeney; Michelle van Rossum; Katja H Aben Journal: Dermatology Date: 2019-09-10 Impact factor: 5.366
Authors: Anna Crispo; Maria Teresa Corradin; Erika Giulioni; Antonella Vecchiato; Paolo Del Fiore; Paola Queirolo; Francesco Spagnolo; Vito Vanella; Corrado Caracò; Giulio Tosti; Elisabetta Pennacchioli; Giuseppe Giudice; Eleonora Nacchiero; Pietro Quaglino; Simone Ribero; Monica Giordano; Desire Marussi; Stefania Barruscotti; Michele Guida; Vincenzo De Giorgi; Marcella Occelli; Federica Grosso; Giuseppe Cairo; Alessandro Gatti; Daniela Massa; Laura Atzori; Nicola Calvani; Tommaso Fabrizio; Giuseppe Mastrangelo; Federica Toffolutti; Egidio Celentano; Mario Budroni; Sara Gandini; Carlo Riccardo Rossi; Alessandro Testori; Giuseppe Palmieri; Paolo A Ascierto Journal: Front Oncol Date: 2021-07-08 Impact factor: 6.244